scholarly journals Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine

2001 ◽  
Vol 12 (9) ◽  
pp. 1221-1230 ◽  
Author(s):  
J.F. Vansteenkiste ◽  
J.E. Vandebroek ◽  
K.L. Nackaerts ◽  
P. Weynants ◽  
Y.J. Valcke ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Benefit ◽  
Single Agent ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Clinical Benefit Response ◽  
Phase Iii Study

A Randomized Phase III Study of Single-Agent Amrubicin Vs. Carboplatin/Etoposide in Elderly Patients With Extensive-Disease Small-Cell Lung Cancer

2014 ◽  
Vol 15 (2) ◽  
pp. 96-102 ◽  
Author(s):  
Ikuo Sekine ◽  
Hiroaki Okamoto ◽  
Takeshi Horai ◽  
Kazuhiko Nakagawa ◽  
Hironobu Ohmatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Single Agent ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Extensive Disease ◽  
Phase Iii Study

scholarly journals MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

2017 ◽  
Vol 12 (1) ◽  
pp. S378-S379 ◽  
Author(s):  
Young Kim ◽  
Toyoaki Hida ◽  
Hiroshi Nokihara ◽  
Masashi Kondo ◽  
Koichi Azuma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Phase Iii Study ◽  
Alk Positive
Sign in / Sign up

Export Citation Format

Share Document